Emmaus Life Sciences's EBIT per Share for the
three
months ended in Sep. 2023 was $0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.02.
During the past 3 years, the average EBIT per Share Growth Rate was -7.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 69.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 66.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Emmaus Life Sciences's EBIT per Share or its related term are showing as below:
EMMA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -622.7 Med: 20.35 Max: 96
Current: -7.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Emmaus Life Sciences was 96.00% per year. The lowest was -622.70% per year. And the median was 20.35% per year.
EMMA's 3-Year EBIT Growth Rate is ranked worse than 63.14% of 1305
companies
in the Biotechnology industry
Industry Median: 3.2
vs EMMA: -7.50
Emmaus Life Sciences's EBIT for the
three
months ended in Sep. 2023 was $2.01 Mil.
Emmaus Life Sciences EBIT per Share Historical Data
The historical data trend for Emmaus Life Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (OTCPK:EMMA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Emmaus Life Sciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Emmaus Life Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Emmaus Life Sciences (Emmaus Life Sciences) Business Description
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EMMA has been successfully added to your 